Curative Biotechnology(CUBT)
$0.62-0.04 (-5.92%)
CUBT
Curative Biotechnology financials statements
$0.62
At close:-0.04 (-5.92%)
Curative Biotechnology (CUBT) Ratios
20 Followers
Curative Biotechnology Ratios
CUBT's free cash flow for Q2 2026 was $-341.83K. For the 2026 fiscal year, CUBT's free cash flow was increased by $0.00 and operating cash flow was $-341.83K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.01 | 0.03 | 0.11 | 0.01 | 1.03 |
| Quick Ratio | 0.01 | 0.03 | 0.11 | 0.01 | 1.03 |
| Cash Ratio | 0.01 | 0.00 | 0.01 | 0.01 | 0.92 |
| Solvency Ratio | -0.27 | -0.49 | -0.67 | -0.23 | -0.28 |
| Operating Cash Flow Ratio | -0.11 | -0.14 | -0.08 | -0.33 | -2.20 |
| Short-Term Operating Cash Flow Coverage | -0.64 | -0.75 | -0.22 | -1.37 | 0.00 |
| Net Current Asset Value | $ -8.09M | $ -6.86M | $ -5.14M | $ -22.55M | $ -18.02M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.64 | 0.63 | 0.87 | 0.51 | 0.00 |
| Debt-to-Equity Ratio | -0.22 | -0.28 | -0.72 | -0.42 | 0.00 |
| Debt-to-Capital Ratio | -0.29 | -0.39 | -2.55 | -0.73 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.35 | -0.44 | -0.83 | -0.82 | 1.43 |
| Debt Service Coverage Ratio | -0.60 | -0.94 | -0.69 | -2.71 | -29.19 |
| Interest Coverage Ratio | -1.50 | -2.17 | -1.42 | -4.86 | -28.38 |
| Debt to Market Cap | 0.00 | 0.12 | 0.16 | 0.10 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.41 | 0.01 | 0.00 | 0.00 |
| Net Debt to EBITDA | -0.93 | -0.57 | -0.88 | -0.23 | 0.13 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 99.99% | 100.00% |
| EBT Per EBIT | 150.66% | 146.05% | 204.71% | 120.45% | 106.50% |
| Return on Assets (ROA) | -107.30% | -164.79% | -152.01% | -257.52% | -221.38% |
| Return on Equity (ROE) | 37.18% | 72.57% | 125.91% | 211.95% | -317.51% |
| Return on Capital Employed (ROCE) | 24.68% | 49.69% | 61.51% | 177.89% | -298.13% |
| Return on Invested Capital (ROIC) | 31.76% | 68.88% | 218.60% | 322.25% | -298.13% |
| Return on Tangible Assets | -282.17% | -437.51% | -335.11% | -1156.90% | -625.59% |
| Earnings Yield | -0.27% | -30.68% | -28.06% | -47.80% | -20.50% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.02 | 0.03 | 0.00 | 0.01 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -16333.97 | -13053.54 | -157548.87 | -39341.63 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 16333.97 | 13053.54 | 157548.87 | 39341.63 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.17 | -0.00 | -0.00 | -0.00 |
| Free Cash Flow Per Share | -0.00 | -0.17 | -0.00 | -0.00 | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | -217216.50 | 0.00 | -34.65 | -19.97 | -75.19 |
| Capital Expenditure Coverage Ratio | -217216.50 | 0.00 | -34.65 | -19.97 | -75.19 |
| Operating Cash Flow Coverage Ratio | -0.64 | -0.75 | -0.22 | -1.43 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -0.11% | -8.80% | -3.55% | -14.33% | -6.24% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -270.00 | -3.26 | -3.56 | -2.09 | -4.88 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -135.42 | -2.37 | -4.49 | -4.43 | 15.49 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -948.65 | -11.36 | -28.17 | -6.98 | -16.03 |
| Price-to-Operating Cash Flow Ratio | -948.65 | -11.36 | -28.99 | -7.33 | -16.24 |
| Price-to-Earnings Growth (PEG) Ratio | 2.71 | 0.06 | 0.35 | 0.03 | -0.03 |
| Enterprise Value Multiple | -583.76 | -5.52 | -6.52 | -2.81 | -4.92 |
| Enterprise Value | 825.56M | 12.97M | 16.31M | 12.27M | 25.38M |
| EV to EBITDA | -583.76 | -5.52 | -6.52 | -2.81 | -4.92 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -950.16 | -12.68 | -32.57 | -7.61 | -15.62 |
| EV to Operating Cash Flow | -950.16 | -12.68 | -33.51 | -7.99 | -15.82 |
| Tangible Book Value Per Share | -0.01 | -1.03 | -0.01 | -0.04 | -0.04 |
| Shareholders’ Equity Per Share | -0.01 | -0.81 | -0.00 | -0.00 | 0.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | -0.22 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.00 | -0.59 | -0.01 | -0.01 | -0.01 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.51 | 1.46 | 1.52 | 1.21 | 1.03 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.38 | 0.29 | 0.12 | 0.29 | 0.30 |
Currency in USD

